Manipal College of Pharmaceutical Sciences Manipal Academy of Higher Education, Manipal BPharm Semester VIII - End Semester Examination – July 2021 PPR-BP805ET: PHARMACOVIGILANCE

Date: 09-07-2021

Duration: 2:30pm to 4:30pm

Max. Marks: 50

Multiple Choice Questions

- 2. Which of the following scale is not used for the causality assessment of adverse drug reactions?
 - A. French imputation method
 - B. Karch and Lasagna's
 - C. Modified Hartwig and Seigel
 - D. Naranjo scale
- 3. Incidence adverse drug reaction (ADR) more than 10 percent is called ------
 - A. Common ADR
 - B. Rare ADR
 - C. Very common ADR
 - D. Very rare ADR
- 4. Response of adverse reaction upon cessation of drug is referred as -----response
 - A. Dechallenge
 - B. Probable
 - C. Rechallenge
 - D. Unlikely
- 5. USFDA maintains a voluntary ADR reporting system through its ------programme
 - A. MedWatch
 - B. MHRA
 - C. Vigibase
 - D. Vigiflow
- 6. The main use of ATC system is for
 - A. Better marketing decisions
 - B. Drug utilization studies
 - C. Identifying counterfeit drug
 - D. Regulatory approval of drugs

7. To make INN universally available, they are tA. IUPACB. UMC	formally placed by in public domain
C. USFDA	
D. WHO	
2. 1110	
 In Eudravigilance, the reaction monitoring rep A. Clinical Trail reports 	port is used for
B. Multi-Axial terminology	
C. Regulatory reports	
D. Signal Detection	
9 aims to detect adverse events ear appropriate response (risk-management) to the A. Adverse drug reactions	rly to trigger accurate risk assessment and problem
B. Drug Interactions	
C. Hemovigilance	
D. Vaccine pharmacovigilance	
10. Communication is a part of skills	
A. Hard	
B. Rough	
C. Short	
D. Soft	
A. describe a new pathogen B. describe presentation of disease C. recognize common manifestation of a known D. recognize known adverse reaction of a drug	n disease
12. Following is an active surveillance method for a A. Case series	dverse drug reaction monitoring
B. Drug event monitoring	
C. Spontaneous reports	
D. Stimulated reporting	
= - S smitstated reporting	
 13. Pharmacovigilance documents intended to provide of a medicinal product at defined time points after A. Expedited reports B. Individual case safety reports C. Periodic safety update report 	de an evaluation of the risk-benefit balance er its authorization.
D. Spontaneous report	

14	help researchers to lear	n more about the treatn	nent and doing a service to future
	patients.		
A.	A. Phase I studies		
В	B. Phase II studies		
C	C. Phase III studies		
Γ	D. Phase IV studies		
		C.1 11 1	
	The enzyme that metabolizes most	of the medicines is	
-	A. CYP1A2		
	3. CYP2C19		
	C. CYP2C9		
L	D. CYP2D6		
16	test will identify the	e vulnerable patients to l	hemolysis with certain drugs.
	A. DPD deficiency	1	, c
	B. G6PD deficiency		
	C. HLA-B variants		
	D. UGT1A1 variants		
	1		
17. B	Beers Criteria is		
A	a. potentially appropriate medicati	ions to avoid in older ac	lults with certain conditions
В	b. potentially appropriate medicati	ions to avoid in pediatri	cs with certain conditions
C	c. potentially inappropriate medical	ations to avoid in older	adults with certain conditions
. D	D. potentially inappropriate medical	ations to avoid in pediat	rics with certain conditions
	Which one of the drug is an example	le for pregnancy categor	ry X?
A	A. Gentamicin		
	. Losartan		
	2. Metformin		
D). Methotrexate		
10 T	he clinical trial and new drug deve	elonment in India are ex	plained in
	A. Schedule H	cropment in maia are ex	pranted in
	Schedule M		4.
	C. Schedule X		
	D. Schedule Y		
ט	. Schedule 1		
20. In	general, polypharmacy has been	defined as	
	a single patient taking more than		
	. multiple medications prescribed		sease
	. multiple medications taken to m		
	the prescription of two drugs that		

Short Answer Questions		6x5 Marks
1	Explain the Hartwig's severity assessment of adverse drug reactions.	5 Marks
2	Describe the structure of ATC system and explain the purpose of	5 Marks
	ATC/DDD system.	
3	Discuss establishment of pharmacovigilance program in a hospital.	5 Marks
4	Explain the importance of effective communication in pharmacovigilance	5 Marks
	with it challenges.	
5	Write the ICH standards for individual case safety reports (ICSRs).	5 Marks
6	Discuss single dose toxicity studies in schedule Y.	5 Marks